Pemvidutide 2026: PERFORMA Phase 3, RESTORE ALD Trial & Dosage Data

Pemvidutide (ALT-801) now spans four indications. See the MOMENTUM, IMPACT, RECLAIM and RESTORE trial results, dosage data, safety profile, and how it compares to tirzepatide and retatrutide.